Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Advanced Preventive Women's Clinic For Women With Menopause Symptoms Who Are At Risk For Heart Disease
Women who are at risk for heart disease and who are also experiencing menopause symptoms now have an added re a highly specialized clinic in the Division of Cardiology at the Cedars-Sinai Heart Institute. The Advanced Preventive Women"s Clinic at the Women"s Heart Center recently opened and is offering comprehensive cardiac risk assessments designed specifically for women who are in menopause. The clinic also offers menopausal patients state-of-the-art screenings, as well as personalized medicine therapies and counseling, including high-risk hormone counseling.
generic viagra online
Texas Lawmakers Divert Millions From Family Planning Clinics To Community Health Centers
Specialty clinics that provide family planning services in Texas have seen a significant decrease in state funding over the past four years because lawmakers have redirected millions of dollars to expand family planning at community health centers, the Dallas Morning News reports. The funding changes began in 2005, when lawmakers said they were shifting funding to community health centers because they offered more comprehensive health care to low-income patients. Advocates for the family planning clinics argue that the policy is an attempt by antiabortion-rights advocates to shut the clinics down. Although clinics that receive state funding are prohibited from offering abortion services, some conservative lawmakers believe that limiting the funding will hurt groups like Planned Parenthood, which offers abortion services at other locations, according to some family planning advocates. The Morning News reports that state lawmakers might return some of the funding to the specialty clinics during the current legislative session; however, the funding only would equal any money left unused by the community health centers.The most significant funding change occurred in 2005, when almost 25% of the state"s $45 million annual family planning budget was set aside for "federally qualified health centers" -- community health centers that offer services to uninsured and underserved people. Advocates for family planning clinics say that the number of patients receiving state-funded reproductive services declined by nearly 22%, from 326,000 patients in 2005 to 255,000 in the last fiscal year. They also note that the community health centers have an unused surplus of more than $11.5 million since 2005, which they say the family planning clinics could have used.According to the Morning News, many public health experts believe that specialty clinics that have family planning services offer more efficient and effective reproductive care than community health centers. David Warner, a health care finance and policy expert at the University of Texas Lyndon B. Johnson School of Public Affairs, said the specialty clinics are "very targeted" and "don"t have a lot of overhead," whereas the community clinics have "limited enrollment and can be a lot less accessible." He added, "Continuing to starve those clinics means that you"re not going to be reaching the number of people you could be reaching with family planning services." Family planning clinics in Texas offer more than a dozen services ranging from birth control prescriptions to breast and cervical cancer screening and sexually transmitted infection testing. However, reproductive health advocates say many people often associate the clinics with abortion services, which gives antiabortion-rights lawmakers an incentive to shut down the clinics by withholding funding. Fran Hagerty, CEO of the Women"s Health and Family Planning Association of Texas, said, "Some lawmakers believe if they can prevent Planned Parenthood from participating in the state"s family planning program, then they"ve accomplished their goal."Supporters of community health centers say that billing issues and other administrative problems have distorted their data on how many reproductive health patients they are treating. Many women receive care at the community centers for family planning services along with treatment of other health problems, so they often are not recorded as reproductive health patients, according to the centers (Ramshaw, Dallas Morning News, 5/22).
News of the day
Advanced Preventive Women's Clinic For Women With Menopause Symptoms Who Are At Risk For Heart Disease
Women who are at risk for heart disease and who are also experiencing menopause symptoms now have an added re a highly specialized clinic in the Division of Cardiology at the Cedars-Sinai Heart Institute. The Advanced Preventive Women"s Clinic at the Women"s Heart Center recently opened and is offering comprehensive cardiac risk assessments designed specifically for women who are in menopause. The clinic also offers menopausal patients state-of-the-art screenings, as well as personalized medicine therapies and counseling, including high-risk hormone counseling.
Diagnostics

Lymphoma Research Funded By Millennium Pharmaceuticals Inc./Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Nebraska. Lymphoma, the most common type of blood cancer, is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to a 2008 report from the World Health Organization, there are six types of HL and over 61 types of NHL; many of which are rare diseases. A member of LRF"s Mantle Cell Lymphoma Consortium (MCLC), Dr. Fu"s work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of NHL accounting for 6 percent of all new diagnoses of NHL or approximately 3,000 new cases per year in the United States. Mantle cell usually affects men over 60 and is frequently diagnosed as a Stage IV disease, often present in lymph nodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow. MCL is characterized by over expression of the gene cyclin D1 due to a chromosomal translocation. A subset of MCL also expresses higher levels of a group of small RNA molecules, called miR-17~92. Dr. Fu and his co-workers have found that higher expression of miR-17~92 is directly correlated with poorer patient survival. These findings indicate that higher miR-17~92 expression induces abnormal activation of a pathway in tumor cells that leads to increased resistance to standard chemotherapy. Dr. Fu will conduct a pre-clinical study to determine whether suppression of miR-17~92 will improve the effect of chemotherapy. His study will thus provide a novel approach to treating MCL patients. "Dr. Fu"s elegant proposal explores a new avenue for understanding MCL and identifying potential therapeutic targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, Hematologic Malignancy Program - University of Virginia and Chair of LRF"s Mantle Cell Consortium. The 3-year Clinical Investigator Career Development Award is designed to fund training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma. The focus of the training is to prepare clinicians to design and administer clinical studies in lymphoma and to take on the primary responsibilities for clinical trial design, protocol writing, Institutional Review Board (IRB) submission, and publication. Dr. Fu will be pursuing a Career Development Plan with the guidance of his mentor, Dr. Wing Chan, Co-Director, Center for Lymphoma and Leukemia Research, at the University of Nebraska Medical Center, Omaha, NE. Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The Takeda Oncology Company for their generous support of this grant. "We are proud to be able to support lymphoma research through grants such as this one, and we are hopeful that the work we support may someday be a significant contribution to the discovery of new methods for treating blood cancer," said Dixie-Lee Esseltine, MD, Vice President, Global Medical Affairs, Millennium. "The Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation clinical Investigator Career Development Award is supported by an independent grant from Millennium Pharmaceuticals, Inc. (Millennium). Millennium neither controlled nor influenced the nomination or selection of any award recipient." About the Mantle Cell Lymphoma Consortium (MCLC) Established by LRF in January 2005, the MCLC is comprised of more than 100 laboratory and clinical scientists from North America and Europe who focus their research on mantle cell lymphoma (MCL). The Consortium is designed to accelerate the understanding and treatment of MCL by bringing together these lead investigators, funding innovative studies and creating important res such as the MCL website and cell bank. About the Lymphoma Research Foundation The Lymphoma Research Foundation (LRF) is the nation"s largest voluntary health organization devoted exclusively to funding lymphoma research and providing patients and healthcare professionals with critical information on the disease. LRF"s mission is to eradicate lymphoma and serve those touched by this disease. As of June 30, 2008, LRF has funded over $37 million in lymphoma-specific research. The Foundation is the world"s largest private funder of mantle cell lymphoma research. LRF also provides a comprehensive series of programs and services for patients, survivors and loved ones affected by lymphoma, including our toll-free Lymphoma Helpline and Clinical Trials Information Service, in-person patient education programs, web casts/teleconferences and support services. Marion F. Swan Lymphoma Research Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009